Kasten, Mary J.
Lahr, Brian D.
Parisapogu, Anusha
Yetmar, Zachary A.
O’Horo, John C.
Orenstein, Robert
Moreno Franco, Pablo
Razonable, Raymund R.
Vergidis, Paschalis
Shah, Aditya S.
Enzler, Mark J.
Inwards, David J.
Bauer, Philippe R.
Funding for this research was provided by:
Mayo Clinic
Article History
Received: 22 September 2023
Accepted: 22 November 2023
First Online: 1 December 2023
Competing interests
: Mary J. Kasten, M.D.: Stockholder: Abbott Laboratories, AbbVie, Amgen, Eli Lilly, Bristol Myers Squib, Amgen, Merck, GlaxoSmithKline, Baxter International, Pfizer, CVS Health Corporation, Viatris Inc, Medtronic, Zimmer Biomet, Masimo Corp, Takeda Pharmaceutical John C. O’Horo, M.D., M.P.H.: Grants from Nference, Inc and the MITRE corporation for COVID-19 research unrelated to the present work. Raymund R. Razonable, M.D.: research grants (funds to the institution) from Gilead, Regeneron and Roche; member of the Data and Safety Monitoring Board (Novartis) and Endpoint Adjudication Committee (Allovir); member of the Board of Directors, American Society of Transplantation Paschalis Vergidis, M.D.: research support from Ansun, Cidara, Scynexis and consultant AbbVie with all fees being paid to Mayo Clinic All other authors declare no conflicts of interests.